Nuvectis Pharma
NVCT
47 hedge funds and large institutions have $24.2M invested in Nuvectis Pharma in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
42% more funds holding
Funds holding: 33 → 47 (+14)
21% more capital invested
Capital invested by funds: $20M → $24.2M (+$4.16M)
15% more call options, than puts
Call options by funds: $569K | Put options by funds: $495K
6.77% more ownership
Funds ownership: 8.75% → 15.52% (+6.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.81M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.36M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$1.08M |
| 5 |
State Street
Boston,
Massachusetts
|
+$778K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$918K |
| 2 |
Millennium Management
New York
|
-$816K |
| 3 |
Goldman Sachs
New York
|
-$446K |
| 4 |
Jane Street
New York
|
-$413K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$321K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$108K | -11,012 | Closed |
|
|
BZWA
52
Blue Zone Wealth Advisors
Los Angeles,
California
| – | -$102K | -10,424 | Closed |
|
53
Citadel Advisors
Miami,
Florida
| – | -$93.8K | -10,344 | Closed |
|
|
JG
54
Jain Global
New York
| – | -$99.2K | -10,154 | Closed |
|
|
AW
55
Avion Wealth
The Woodlands,
Texas
| – | +$508 | +56 | New |
|
NVCT Hedge Fund Activity: Q2 2025 in Review
47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2025, worth a combined $24.2M — up 21% from $20M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NVCT positions and 8 closed out — a net gain of 14 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $5.21M. The largest seller was UBS Group, cutting an estimated $918K.
- 47 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2025, up from 33 in Q1 2025.
- Funds reported $24.2M of Nuvectis Pharma stock for Q2 2025, up 21% quarter-over-quarter.
- 22 funds opened new Nuvectis Pharma positions in Q2 2025 and 8 closed out, a net change of +14 holders.
- The largest Nuvectis Pharma buyer in Q2 2025 was BlackRock, an estimated $5.21M added.
- The largest Nuvectis Pharma seller in Q2 2025 was UBS Group, an estimated $918K sold.
Based on aggregated 13F filings for Q2 2025.